193 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
in the future will be incurred in support of our current and future preclinical and clinical development projects. Due to the inherently unpredictable nature
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good … as if such payment had not been made or such enforcement or setoff had not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations
6-K
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
also contains representations, warranties, indemnification and other provisions customary for transactions of this nature.
JonesTrading
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
market, the liquidity of the pre-funded warrants will be limited.
The warrants are speculative in nature.
The warrants do not confer any rights … loss of the purchase price of their warrants. This risk reflects the nature of a warrant as an asset that, other factors held constant, tends
20-F/A
hv78rqxz67jfqns
26 Mar 24
Annual report (foreign) (amended)
4:57pm
F-3
fxf7c889c9qv
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
s128pjing7hs6cg951bn
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
qtkgnvdm
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
7eipl
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
7q6j8vuy8owjbefd
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
neejsvs ijgugcpc
30 Aug 23
Current report (foreign)
6:45am
6-K
1gpi74 qu6qs1tz4
8 Aug 23
Current report (foreign)
5:25pm
6-K
EX-99
k4l8u
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
m9pimzqe5n 82b43
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
merjc5lqqopoyhbct3g
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
li07jwmsjfqw9y8hvf
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
3o09b rzvc
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
uf6oq9wklisiacko0j
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am